A Study of NIDO-361 in Patients With SBMA

Last updated: October 23, 2024
Sponsor: Nido Biosciences, Inc.
Overall Status: Active - Not Recruiting

Phase

2

Condition

Myasthenia Gravis (Chronic Weakness)

Muscular Dystrophy

Treatment

NIDO-361

Placebo

Clinical Study ID

NCT06411912
NIDO-361-002
  • Ages 18-70
  • Male

Study Summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy of NIDO-361 in adult patients with Spinal and Bulbar Muscular Atrophy (SBMA).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Ambulatory male

  • Documented SBMA diagnosis confirmed by DNA genetic testing

  • Able to complete six-minute walk test (6MWT)

Exclusion

Exclusion Criteria:

  • Clinically significant cardiovascular, endocrine, hepatic, renal, pulmonary,gastrointestinal, neurologic, immunologic, malignant, metabolic, psychiatric, orother condition that, in the opinion of the Investigator, precludes theparticipant's safe participation in the study or would interfere with the studyassessments

  • Inability to undergo MRI (mild sedation may be allowed)

Study Design

Total Participants: 54
Treatment Group(s): 2
Primary Treatment: NIDO-361
Phase: 2
Study Start date:
March 01, 2024
Estimated Completion Date:
October 01, 2025

Connect with a study center

  • Rigshospitalet, Klinik for Nerve- og Muskelsygdomme & Copenhagen Neuromuscular Center

    Copenhagen,
    Denmark

    Site Not Available

  • IRCCS Istituto Neurologico Carlo Besta

    Milano,
    Italy

    Site Not Available

  • Azienda Ospedale Università di Padova

    Padova,
    Italy

    Site Not Available

  • Kyungpook National University Chilgok Hospital

    Daegu,
    Korea, Republic of

    Site Not Available

  • University of College London Hospital (UCLH)

    London,
    United Kingdom

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.